3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
2
Stroke
1
Recurrence
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Inflammatory Breast Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Communication
1
Colorectal Neoplasms
1
Caregiver Burden
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Brain Neoplasms
1
Brain Injuries, Traumatic
1
Brain Injuries
1
Advanced Malignant Solid Neoplasm
1
Interventions
Temozolomide
18
Radiation
7
Magnetic Resonance Spectroscopy
7
Radiotherapy
6
Specimen Handling
4
Lomustine
4
Bevacizumab
4
Aminolevulinic Acid
3
veliparib
2
trametinib
2
lutetium Lu 177 dotatate
2
dabrafenib
2
azeliragon
2
Surgical Procedures, Operative
2
Receptors, Interleukin-8B
2
Nivolumab
2
D2C7-(scdsFv)-PE38KDEL
2
Carboplatin
2
Biopsy
2
varlilumab
1
ulixertinib
1
tinostamustine
1
selinexor
1
ruxolitinib
1
ribociclib
1
relatlimab
1
regorafenib
1
peposertib
1
pembrolizumab
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Palliative Care
×
30 days
×
Clear all
NCT07590726
2026-05-19
PIRe
Rigshospitalet, Denmark
Phase NA
Not yet recruiting
160 enrolled